

Singapore launches new national consortium to advance clinical research

12 April 2022 | News

To support Ministry of Health's and national priorities by identifying impactful health-tech innovation

The Consortium for Clinical Research and Innovation, Singapore (CRIS) has been established to bring together five key national R&D, clinical translation and service initiatives that are under the stewardship of the Ministry of Health.

These are:

1. Singapore Clinical Research Institute (SCRI)
2. National Health Innovation Centre, Singapore (NHIC)
3. Advanced Cell Therapy and Research Institute, Singapore (ACTRIS)
4. Precision Health Research, Singapore (PRECISE)
5. Singapore Translational Cancer Consortium (STCC)

At the CRIS official launch ceremony, two of CRIS's initiatives – ACTRIS and SCRI – announced the following partnerships:

ACTRIS and NUS Yong Loo Lin School of Medicine has jointly launched a professional certification course on the principles and practice of cell therapy. This course is the first of its kind in Asia and will equip healthcare professionals and biomedical personnel with the necessary training and knowledge in immuno-therapeutics.

SCRI will be partnering a local health-tech company Oncoshot to leverage its technology which has the potential to significantly enhance the initiation, screening and enrolment of patients into oncology trials conducted at public healthcare institutions. R

Moving ahead, CRIS aims to build networks and collaborations for regional clinical trials, perform cost-effectiveness assessments for healthcare interventions, and foster industry engagement to fulfil the CRIS Vision – “to nurture and build cutting edge capabilities and innovation in clinical research and translation for Singapore”.